Anastrozole is NOT Recommended for Female-to-Male Gender Transition
Anastrozole should not be used as part of hormone therapy for female-to-male transitioning, as there is no evidence supporting its use in this population, and it carries significant risks including severe bone loss and fractures without any demonstrated benefit for gender transition outcomes. 1
Why Anastrozole is Inappropriate for FtM Transition
FDA-Approved Indication is Exclusively Breast Cancer
- Anastrozole is FDA-approved only for postmenopausal women with hormone receptor-positive breast cancer, not for gender transition 2, 3
- All clinical evidence and guidelines address its use in oncology settings, specifically for estrogen suppression in breast cancer treatment 4, 5
Mechanism Does Not Support FtM Transition Goals
- Anastrozole works by blocking aromatase enzyme, which converts testosterone to estradiol 6, 4
- In FtM transition, the goal is testosterone supplementation to achieve masculinization, not estrogen suppression alone 7
- The drug was designed to suppress estrogen in postmenopausal women who already have minimal estrogen production, not to facilitate masculinization 8, 9
Critical Safety Concerns That Make This Dangerous
Severe Bone Loss Risk
- Anastrozole significantly increases fracture risk, with 7.1% fracture incidence versus 4.1% with tamoxifen after only 37 months of use 1
- The drug causes increased bone resorption markers and decreased spine and hip bone mineral density 1
- Severe osteoporosis (T-score < -4 or >2 vertebral fractures) is an absolute contraindication to anastrozole use 7, 6
- All patients require baseline DEXA scan, calcium supplementation (1200 mg daily), vitamin D (400-600 IU daily), and consideration of bisphosphonates before even considering this medication 7, 6
Premenopausal Use is Contraindicated
- Aromatase inhibitors are ineffective and contraindicated in premenopausal women without ovarian suppression 10, 6
- The drug requires near-absent ovarian function to work properly, as it was designed for postmenopausal women 11, 8
- Using anastrozole in premenopausal individuals (which includes most FtM patients at transition initiation) is explicitly not recommended 10
What Should Be Used Instead for FtM Transition
Standard of Care: Testosterone Therapy
- The appropriate hormone therapy for FtM transition is testosterone supplementation, not aromatase inhibition 7
- Testosterone therapy directly achieves masculinization goals including voice deepening, facial hair growth, muscle mass increase, and fat redistribution
- Monitoring testosterone levels every 6-12 months is the standard approach 7
When Aromatase Inhibitors Might Be Considered (Rare Exception)
- The only scenario where anastrozole appears in transgender medicine literature is for men already on testosterone replacement therapy who develop problematic estradiol elevation due to excessive aromatization 7, 6
- Even in this context, the dose studied is 0.5 mg three times weekly (not daily), and only after documenting estradiol >60 pg/mL or 40-60 pg/mL with symptoms 6
- This represents management of a complication, not primary transition therapy 7
Common Pitfall to Avoid
Do not confuse the off-label use of anastrozole in cisgender men on testosterone therapy (to manage elevated estrogen) with its use in FtM transition. These are completely different clinical scenarios. FtM patients need testosterone supplementation as primary therapy, not estrogen suppression as monotherapy 7, 6.